Article Text

P175 Single centre experience of the real-life impact of pirfenidone on lung function in patients with idiopathic pulmonary fibrosis
  1. A Rathnapala,
  2. A Fries,
  3. Y West,
  4. LP Ho,
  5. RK Hoyles
  1. Oxford Centre for Respiratory Medicine, Oxford, UK


Introduction Idiopathic pulmonary fibrosis (IPF) is a progressively destructive lung disease that culminates in respiratory failure and death. Trials have demonstrated that treatment of IPF patients with Pirfenidone reduces %FVC decline, improves progression-free survival and significantly reduces the risk of all-cause mortality at 1 year. Our anecdotal experience is that a small proportion of patients show improvement of %FVC with treatment.

Objectives To assess the proportion of patients in an ILD specialist centre that improve, stabilise or decline in their %FVCs on Pirfenidone treatment.

Methods In this retrospective study patients with IPF diagnosed according to the ATS/ERS guidelines at the ILD MDT, who were commenced and continued on Pirfenidone for >6 months were included. Data was derived from the clinical records of the Oxford IPF clinic.

Results 100 patient records were analysed and 31 were excluded (n = 15 <6 months’ therapy, n = 5 inadequate data, n = 2 death <1 month, n = 9 other). 58 (84.1%) male, 11 (15.9%) female; 38 (55.1%) had Definite IPF, 31 (44.9%) Probable IPF.

Six months after commencing Pirfenidone (n = 69 patients), 5 (7.25%) experienced significant (>10%) and 9 (13.04%) experienced marginal (5–10%) improvement in %FVC, 33 (47.83%) showed stability (−5% to 5% change %FVC), 10 (14.49%) showed marginal decline (−5% to −10%) and 12 (17.39%) showed significant (>10%) decline in %FVC.

After one year of Pirfenidone (n = 44 patients), 3 (6.8%) showed significant and 5 (11.4%) showed marginal improvement, 18 (40.9%) showed stability, 11 (25%) showed mild and 7 (15.9%) showed significant decline of %FVC.

After 2 years of treatment (n = 15 patients), 1 (6.7%) showed significant and 3 (20%) showed mild improvement, 4 (26.7%) showed stability, 3 (20%) showed mild and 4 (26.7%) showed significant decline of the %FVC.

Among 8 patients who had improvement in %FVC at one year, 6 were males, 6 had definite IPF, median age 77 years (68 – 84) and the median FVC was 73.5% predicted (66 – 79).

Conclusions Real-life use of Pirfenidone shows clear slowing of decline in the %FVC, whereas a clinically significant subset show improvement in FVC. Potentially the beneficial effect is lost after 22–24 months, although small numbers limit this analysis.

Abstract P175 Figure 1

Pre and Post- pirfenidone treatment

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.